OBE022 + atosiban

**OBE022 + atosiban** is a combination therapy evaluated for the prevention of preterm labor. OBE022 (ebopiprant) is a novel, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist aimed at reducing inflammation and uterine contractions by blocking the action of PGF2α, a key driver of myometrial contractility. Atosiban is a peptide oxytocin and vasopressin receptor antagonist used intravenously as a tocolytic agent to suppress premature labor by inhibiting oxytocin-mediated uterine contractions and reducing prostaglandin release. This combination is being studied as a sequential or simultaneous regimen for women with threatened preterm labor to prolong pregnancy by targeting complementary pathways that control uterine activity[3][1][4].

Brand names

Tractocile

Other names

TractocileCAP-449CAP449CAP 449CAP-476CAP476CAP 476CAP-581CAP581CAP 581F-314F314F 314ORF 22164ORF22164ORF-22164RW-22164RW22164RW 22164RWJ 22164RWJ22164RWJ-22164